Preview

Вопросы гематологии/онкологии и иммунопатологии в педиатрии

Расширенный поиск

Профилактика и лечение тошноты и рвоты (ТИР) у детей и подростков, полу

Аннотация

Несмотря на то, что ТИР, индуцированная цитостатической терапией, редко носит жизнеугрожающий характер, с точки зрения пациентов это одно из наиболее тяжело переносимых осложнений, зачастую имеющее мучительный характер. Кроме того, ТИР может усугублять течение других осложнений и патологических состояний. Современная антиэметическая профилактика позволила значительно снизить частоту развития ТИР у детей и подростков, получающих противоопухолевую терапию, однако, до настоящего времени в детской популяции неадекватный контроль ТИР наблюдается значимо чаще, чем у взрослых, а арсенал противорвотных препаратов в силу регуляторных особенностей исследований лекарственных средств в детской практике обновляется с запозданием. Целью этой статьи является ознакомление с современными стандартами профилактики и лечения ТИР у детей и подростков, а также возможными путями их совершенствования.

Об авторе

Лилия Леонидовна Казакова
врач-детский онколог отделения гематологии/онкологии старшего возраста и нейроонкологии ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России
Россия


Список литературы

1. Жуков Н. В. Профилактика тошноты и рвоты, обусловленных проведением химиотерапии и лучевой терапии // Вопросы гематологии/онкологии и иммунопатологии в педиатрии. - 2010. - Т. 9. - № 2. - С. 13-22.

2. Baxter A, Watcha M, Baxter W, Leong T, Wyatt M. Development and validation of a pictorial nausea rating scale for children. Pediatrics. 2011;127:e1542–9.

3. Dupuis LL, Taddio A, Kerr EN, Kelly A, MacKeigan L. Development and validation of a pediatric nausea assessment tool (PeNAT) for use by children receiving antineoplastic agents. Pharmacotherapy. 2006;26:1221–31.

4. Paw Cho Sing E, Robinson PD, Flank J, et al. Classification of the acute emetogenicity of chemotherapy in pediatric patients: A clinical practice guideline. Pediatr Blood Cancer. 2019;66(5):e27646. doi:10.1002/pbc.27646.

5. Patel P, Robinson PD, Thackray J, et al. Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update. Pediatr Blood Cancer. 2017;64(10):10.1002/pbc.26542. doi:10.1002/pbc.26542.

6. Dupuis LL, Robinson PD, Boodhan S, et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer. 2014;61(8):1506-1512. doi:10.1002/pbc.25063.

7. Flank J, Robinson PD, Holdsworth M, et al. Guideline for the Treatment of Breakthrough and the Prevention of Refractory Chemotherapy-Induced Nausea and Vomiting in Children With Cancer. Pediatr Blood Cancer. 2016;63(7):1144-1151. doi:10.1002/pbc.25955.

8. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update [published online ahead of print, 2020 Jul 13]. J Clin Oncol. 2020;JCO2001296. doi:10.1200/JCO.20.01296.

9. Dupuis L, Boodhan S, Sung L, et al. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2011;57:191–8.

10. De Mulder PHM, Seynaeve C, Vermorken JB et al. Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. Ann Intern Med 1990; 113: 834-40.

11. Olver I, Paska W, Depierre A, et al. A multicentre, double-blind study comparing placebo, ondansetron and ondansetron plus dexamethasone for the control of cisplatin-induced delayed emesis. Ondansetron Delayed Emesis Study Group. Ann Oncol. 1996;7(9):945-952. doi:10.1093/oxfordjournals.annonc.a010798.

12. Warr D, Street J, Carides A. Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of phase 3 trial of aprepitant in patients receiving adriamycin–cyclophosphamide-based chemotherapy. Support Care Cancer. 2011;19:807–13.

13. Hesketh P, Aapro M, Street J, Carides AD. Evaluation of risk factors predictive of nausea and vomitingwith current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy. Support Care Cancer. 2010;18:1171–7.

14. Roscoe JA, Bushunnow P, Morrow GR, et al. Patient experience is a strong predictor of severe nausea after chemotherapy: a University of Rochester Community Clinical Oncology Program study of patients with breast carcinoma. Cancer. 2004;101:2701–8.

15. Dupuis LL, Tamura RN, Kelly KM, Krischer JP, Langevin AM, Chen L, et al. Risk factors for chemotherapy-induced nausea in pediatric patients receiving highly emetogenic chemotherapy.

16. Pediatr Blood Cancer. 2019;66:e27584.

17. Leslie RA, Shah Y, Thejomayen M, Murphy KM, Robertson HA. The neuropharmacology of emesis: the role of receptors in neuromodulation of nausea and vomiting. Can J Physiol Pharmacol. 1990;68:279–88.

18. Endo T, Minami M, Hirafuji M, Ogawa T, Akita K, Nemoto M, et al. Neurochemistry and neuropharmacology of emesis – the role of serotonin. Toxicology. 2000;153:189–201.

19. Tricco AC, Blondal E, Veroniki AA, Soobiah C, Vafaei A, Ivory J, et al. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis. BMC Med. 2016;14(1):216.

20. Kovács G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, noninferiority study. Lancet Oncol . 2016;17(3):332–44.

21. Chaudhary NK, John RR, Boddu D,Mahasampath G, Nesadeepam N, Mathew LG. Palonosetron is a better choice compared with ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in a resource-limited pediatric oncology center:

22. results from a randomized control trial. J Pediatr Hematol Oncol. 2019;41(4):294–7.

23. Tan J,Wang S, Liang X, Li CC, Zhang J, Zhao Z, Kong XR, Deng X, Peng L, Yang C. Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.

24. Pediatr Blood Cancer. 2018;65(2).

25. Alvarez O, Freeman A. Randomized double-blind crossover ondansetron-dexamethasone versus ondansetron-placebo study for the treatment of chemotherapy-induced nausea and vomiting in pediatric patients with malignancies. J Pediatr Hematol Oncol 1995;17:145–150.

26. Phillips R, Gopaul S, Gibson F, et al. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst Rev 2010; 1–87. Art. No.: CD007786. doi: 10.1002/14651858.CD007786.pub2.

27. The Italian Group for Antiemetic Research. Double-blind, dosefinding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol. 1998;16:2937–42.

28. The Italian Group for Antiemetic Research. Randomized, doubleblind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol. 2004;22:725–9 [Erratum, J Clin Oncol 2004;22:2038].

29. Roila F, Ruggeri B, Ballatori E, del Favero A, Tonato M. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized doubleblind study. J Clin Oncol. 2014;32(2):101–6.

30. Hesketh PJ, Grunberg SM, Gralla RJ,Warr DG, Roila F, deWit R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21:4112–9.

31. Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005;23:2822–30.

32. Gore L, Chawla S, Petrilli A, Hemenway M, Schissel D, Chua V, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer. 2009;52:242–7.

33. Aapro MS, Walko CM. Aprepitant: drug–drug interactions in perspective. Ann Oncol. December 2010;21(12):2316–23.

34. Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2020 Feb;21(2):e70]. Lancet Oncol. 2020;21(2):242-249. doi:10.1016/S1470-2045(19)30678-3.

35. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932–47 [Erratum, J Clin Oncol

36. ;24:5341–2.].

37. Ettinger DS, Bierman PJ, Bradbury B, et al. Antiemesis. J Natl Compr Cancer Netw. 2007;5:12–33.

38. Roila F, Hesketh PJ, Herrstedt J, Antiemetic Subcommitte of the Multinational Association of Supportive Care in Cancer. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann

39. Oncol. 2006;17:20–8.

40. Herrstedt J. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis. Ann Oncol. 2007;18(Suppl 2):ii83–5.

41. Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol. 2003;21(22):4112-4119. doi:10.1200/JCO.2003.01.095

42. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97(12):3090-3098. doi:10.1002/cncr.11433

43. dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104(17):1280-1292. doi:10.1093/jnci/djs335.

44. Dupuis L, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60: 1073–82.

45. Bakhshi S, Batra A, Biswas B, Dhawan D, Paul R, Sreenivas V. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer. 2015;23(11):3229-3237. doi:10.1007/s00520-015-2714-9.

46. Kang HJ, Loftus S, Taylor A, DiCristina C, Green S, Zwaan CM. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial [published correction appears in Lancet Oncol. 2015 Sep;16(9):e427]. Lancet Oncol. 2015;16(4):385-394. doi:10.1016/S1470-2045(15)70061-6.

47. Small BE, Holdsworth MT, Raisch DW, Winter SS. Survey ranking of emetogenic control in children receiving chemotherapy. J Pediatr Hematol Oncol 2000; 22: 125–32.

48. Dupuis LL, Nathan PC. Optimizing emetic control in children receiving antineoplastic therapy: beyond the guidelines. Paediatr Drugs 2010; 12: 51–61.

49. Holdsworth MT, Raisch DW, Frost J. Acute and delayed nausea and emesis control in pediatric oncology patients. Cancer 2006; 106: 931–40.

50. Kovacs G, Wachtel AE, Basharova EV, Spinelli T, Nicolas P, Kabickova E. Palonosetron versus ondansetron for prevention of chemotherapyinduced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study. Lancet Oncol. 2016;17(3):332–344.

51. Nadaraja S, Mamoudou AD, Thomassen H, Wehner PS, Rosthoej S, Schroeder H. Palonosetron for the prevention of nausea and vomiting in children with acute lymphoblastic leukemia treated with high dose methotrexate. Pediatr Blood Cancer. 2012;59(5):870–873.

52. Patil V, Prasada H, Prasad K, Shenoy UV. Comparison of antiemetic efficacy and safety of palonosetron vs ondansetron in the prevention of chemotherapy-induced nausea and vomiting in children. J Community Support Oncol. 2015;13(6):209–213.

53. Ripaldi M, Parasole R, De Simone G, et al. Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety. Bone Marrow Transplant. 2010;45(11):1663–1664.

54. Varrasso G, De Grazia A, Mollace MG, Megaro G, Paiano M, Suraci S. Antiemetic efficacy of palonosetron in children receiving moderately emetogenic chemotherapy: preliminary results. Pediatr Blood Cancer. 2013;60:174.

55. Bymaster FP, Falcone JF, Bauzon D, et al. Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine. Eur J Pharmacol. 2001;430(23):341–349. doi:10.1016/S0014-2999(01)01399-1.

56. Srivastava M, Brito-Dellan N, Davis MP, et al. Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage. 2003;25(6):578–782. doi:10.1016/S0885-3924(03)00143-X.

57. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol. 2011;9:188–95.

58. Navari RM, Qin R, Ruddy KJ, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;375(2):134–142. doi:10.1056/NEJMoa1515725

59. Zhang Z., Zhang Y., Chen G., Hong S., Yang Y. et al. Olanzapine-Based Triple Regimens Versus Neurokinin-1 Receptor AntagonistBased Triple Regimens in Preventing ChemotherapyInduced Nausea and Vomiting Associated with Highly Emetogenic Chemotherapy: A Network Meta-Analysis. Oncologist. 2018. Vol. 23(5). P. 603–616.

60. Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(28):3240–3261. doi:10.1200/JCO.2017.74.4789

61. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2011;29:4189-98.

62. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008;5:32-43. [Crossref] [PubMed]

63. Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prvention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016;27:v119-33. [Crossref] [PubMed]

64. Hashimoto H, Abe M, Tokuyama O, et al. Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet Oncol. 2020 Feb;21(2):e70]. Lancet Oncol. 2020;21(2):242-249. doi:10.1016/S1470-2045(19)30678-3.

65. Samsel C, Kearney J, Meadows AL, Abrams A, Hirst JM, Muriel AC. Olanzapine for chemotherapy-induced nausea:Lessons learned from child and adolescent psychiatry. Pediatr Blood Cancer. 2018;65(10):e27289. doi:10.1002/pbc.27289.

66. Flank J, Sung L, Dvorak CC, Spettigue W, Dupuis LL. The safety of olanzapine in young children: a systematic review and meta-analysis. Drug Saf. 2014;37(10):791-804. doi:10.1007/s40264-014-0219-y.

67. Flank J, Thackray J, Nielson D, August A, Schechter T, Alexander S, Sung L, Dupuis LL. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in: A retrospective, multi-center review. Pediatr Blood Cancer 2015;62:496–501.

68. Radhakrishnan V, Pai V, Rajaraman S, et al. Olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced vomiting in children: An open-label, randomized phase 3 trial [published online ahead of print, 2020 Jun 22]. Pediatr Blood Cancer. 2020;e28532. doi:10.1002/pbc.28532.

69. J. Flank1 & T. Schechter1 & P. Gibson2 & D. L. Johnston3 & A. D. Orsey4 & C. Portwine 5 & L. Sung1 & L. L. Dupuis1. Olanzapine for prevention of chemotherapy-induced nausea and vomiting in children and adolescents: a multi-center, feasibility study. Support Care Cancer (2018) 26:549–555 DOI 10.1007/s00520-017-3864-8.

70. Ramavath D. Naik, MD1; Sreenivas Vishnubhatla, PhD2; Vishwajeet Singh, PhD2; Ashwati S. Pillai, BSc1; Deepa Dhawan, MA1; and Sameer Bakhshi, Olanzapine for Prevention of Vomiting in Children and Adolescents Receiving Highly Emetogenic Chemotherapy: Investigator-Initiated, Randomized, Open-Label Trial. DOI: 10.1200/JCO.20.00871 Journal of Clinical Oncology.


Рецензия

Для цитирования:


Казакова Л.Л. Профилактика и лечение тошноты и рвоты (ТИР) у детей и подростков, полу. Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2020;19(4).

Просмотров: 18


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1726-1708 (Print)
ISSN 2414-9314 (Online)